Shots: The P-II EMPOWER CSCC-1 study results involve assessing of Libtayo (cemiplimab-rwlc) in patients with LA & metastatic CSCC and will be presented at ASCO 2019 The P-II EMPOWER CSCC-1 […]readmore
Tags : cemiplimab-rwlc